U.S. Building Stock News

If you are wondering whether Bristol-Myers Squibb at around $54 is a bargain or a value trap, you are not alone. This article is going to unpack that calmly and clearly. After a tough stretch, the stock has bounced with a 5.1% gain over the last week and a strong 16.4% move over the last 30 days, even though it is still down year to date and only modestly up over 1 year. This hints at shifting sentiment rather than a completed turnaround. That recent strength has come as investors refocus on...

Adtalem Global Education (ATGE) has quietly pushed higher, with the stock up about 5% over the past week and modestly positive this month, even after a steep slide in the past 3 months. See our latest analysis for Adtalem Global Education. At a share price of $97.76, Adtalem’s recent bounce, including a strong 1 day share price return and a solid year to date share price gain, contrasts with its sharp 90 day share price pullback. At the same time, its multi year total shareholder return...

Mobileye Global (MBLY) just picked up a meaningful real world win in Europe, with Ruter and Holo teaming up with Volkswagen owned MOIA to deploy ID. Buzz autonomous shuttles in Oslo using Mobileye Drive. See our latest analysis for Mobileye Global. That makes the Oslo win even more noteworthy, because it lands while sentiment has been weak, with a year to date share price return of minus 47.35 percent and a three year total shareholder return of minus 69.92 percent, suggesting long term...

Earlier this month, Bicara Therapeutics reported preliminary Phase 1b data showing that weekly 750 mg ficerafusp alfa plus pembrolizumab was generally well tolerated in first-line HPV-negative recurrent or metastatic head and neck squamous cell carcinoma, and the FDA granted the combination Breakthrough Therapy Designation in this setting. New biomarker findings suggesting stronger TGF-β inhibition and immune activation at the 1,500 mg dose level add scientific weight to Bicara’s ongoing...

Alphabet (GOOGL) has been on a strong run this year, and with shares up 63% year to date and about 23% over the past 3 months, investors are reassessing what they are really paying for. See our latest analysis for Alphabet. That surge in momentum, with a 30 day share price return of 11.51% and a 3 year total shareholder return of 251.14%, suggests investors are increasingly pricing Alphabet as a durable growth and AI infrastructure story rather than just a mature ad business. If Alphabet’s...

In 2025, MP Materials announced record rare earth production, new long-term agreements with the U.S. Department of Defense and Apple worth hundreds of millions of US dollars, and a Saudi refining joint venture backed by government funding to bolster non-Chinese supply chains. Together, these contracts, investments, and partnerships underline MP Materials’ emerging role as a core supplier in Western rare earth and magnet value chains, with government and blue-chip counterparties sharing both...

Chipotle Mexican Grill (CMG) just crossed a big psychological marker, opening its 4,000th restaurant in Manhattan, Kansas, and pairing that milestone with detailed plans for the next leg of its expansion. See our latest analysis for Chipotle Mexican Grill. The 4,000th store and fresh share repurchase firepower come after a choppy stretch, with a double digit 1 month share price return but a sharply negative year to date share price return and still solid multi year total shareholder returns...

If you have been wondering whether Duolingo at around $185 a share is now a bargain or still a pricey growth story, you are not alone. The stock has had a rough patch recently, down about 10.6% over the last week and roughly 42.9% year to date, even though it is still up around 158.3% over the past three years. That slide comes after a period when investors had priced Duolingo as a high growth, category defining language learning platform and are now reassessing what they are willing to pay...

Inspire Medical Systems (INSP) has experienced a volatile ride lately, with the stock dropping over the past week but still sitting well above where it traded a month ago. See our latest analysis for Inspire Medical Systems. Stepping back, that sharp 1 day and 7 day share price pullback comes after a powerful 30 day and 90 day rebound, but longer term total shareholder returns remain deeply negative. This suggests momentum is rebuilding from a still beaten up base. If Inspire’s recent swings...

PJT Partners (PJT) has quietly outperformed over the past year, with shares up about 4% and a strong 3 year total return above 130%. This raises fresh questions about whether the investment bank still looks reasonably priced. See our latest analysis for PJT Partners. The share price has drifted a little over the past quarter but still sits at around $170.03. That modest near term share price weakness contrasts with a much stronger three year total shareholder return, suggesting momentum has...

If you are wondering whether Liquidia is still a smart buy after its huge run, you are not alone. This is exactly the kind of stock where valuation really matters. The share price has pulled back about 2.3% over the last week, but it is still up 21.9% over 30 days and 182.6% year to date, with a 210.0% gain over the past year and 992.3% over five years. Those moves have been driven by growing optimism around Liquidia's pipeline and regulatory progress, with investors reacting positively to...

In the third quarter of 2025, Brandes Small Cap Value Fund disclosed a new position in Prestige Consumer Healthcare, while the company confirmed repurchasing about 4.7% of its shares since mid‑2024 for roughly US$161 million and reiterated fiscal 2026 revenue guidance that still points to a modest organic decline. Together, fresh institutional buying and ongoing buybacks highlight growing confidence in Prestige’s acquisition-led model and its focus on resilient, as-needed over-the-counter...

Genpact (G) just widened its leadership bench, adding three seasoned executives to drive its GenpactNext strategy and deepen its push into advanced AI led technology solutions and next generation clients. See our latest analysis for Genpact. The leadership refresh comes as Genpact’s share price hovers around $47.35, with a 90 day share price return of 14.57 percent and a 1 year total shareholder return of 10.14 percent, suggesting momentum is gradually building as investors reassess its AI...

Wondering if Ulta Beauty at around $591 a share is still worth buying, or if the big gains are already behind it? Let us unpack what the current price really implies about future returns. The stock has barely moved in the last week, but it is up 11.7% over the past month, 37.8% year to date, and 39.2% over the last year, with a 120.5% gain over five years that has rewarded long term holders. Those gains reflect growing confidence in Ulta's position as a go to beauty retailer, from its...

Many investors are wondering if CoreWeave is still a smart buy after its big run or if the easy money has already been made, and that is exactly what we are going to unpack here. The stock has cooled off recently, dropping about 16.1% over the last week and 6.5% over the past month, but it is still up an impressive 80.9% year to date, which suggests sentiment has shifted in a significant way. A lot of this volatility has been driven by headlines around AI infrastructure demand, fresh...

Opendoor Technologies (OPEN) just reshaped its C suite again, naming fintech veteran Lucas Matheson as President and confirming Christy Schwartz as permanent CFO. The company is sharpening its AI and blockchain focused turnaround narrative for investors. See our latest analysis for Opendoor Technologies. Those leadership moves land after a wild year, with the latest share price at $6.46 and a year to date share price return above 300%, but more recently a fading 30 day share price return and...

Oracle (ORCL) has quietly slipped about 17% over the past month and nearly 40% in the past 3 months, even though revenue and net income are still growing at double digit rates year over year. See our latest analysis for Oracle. That slump looks more like a reset than a collapse, given the share price is still at $184.92 and Oracle’s longer term total shareholder return remains very strong, with momentum clearly fading in the near term while the broader growth story stays intact. If Oracle’s...

Lam Research (LRCX) has quietly continued to reward patient investors, with the stock up about 11% over the past month and roughly 36% in the past 3 months, outpacing many semiconductor peers. See our latest analysis for Lam Research. With the share price now around $164.30 and a powerful year to date share price return of roughly 127%, Lam’s momentum looks firmly intact. This echoes its strong multi year total shareholder returns and improving sentiment around semiconductor capital...

Constellium (NYSE:CSTM) has flipped the switch on its new finishing lines at Singen in Germany, completing a EUR30 million battery foil investment with Lotte Infracell that tightens its grip on Europe’s EV supply chain. See our latest analysis for Constellium. That operational step up seems to be catching investors’ attention, with the share price at $18.38 after a strong 30 day share price return and powerful year to date and one year total shareholder returns, suggesting positive momentum...

Amphenol (APH) slid 6.6% after investors bailed on high-flying AI and electronics names when Oracle and Broadcom delivered underwhelming earnings, a reminder that the market is now demanding clearer proof of returns. See our latest analysis for Amphenol. That sharp swing comes after a powerful run, with the share price up strongly on a year to date basis and supported by a very robust multi year total shareholder return. This suggests momentum is cooling, but the long term story remains...

UnitedHealth Group recently faced a series of developments, including leadership changes, ongoing regulatory scrutiny tied to a DOJ investigation, and final court approval of its Amedisys-related divestiture settlement, while also preparing to report its full-year 2025 results and 2026 guidance in early 2026. These shifts, alongside the launch of a leveraged UnitedHealth-focused ETF and continued institutional attention, highlight how questions about management stability, medical cost...

Wondering if ALLETE is still a quietly reliable value play in a choppy utilities market, or if most of the upside has already been priced in? This breakdown is for investors who care less about headlines and more about what the numbers actually say. The stock has inched up about 0.6% over the last week and month, and is up 4.6% year to date, while longer term investors have seen gains of 8.6% over 1 year, 20.4% over 3 years, and 44.3% over 5 years. This reflects a steady climb that suggests...

If you are wondering whether Ciena’s huge run up still leaves any value on the table, or if you are late to the party, this breakdown will help you decide whether the stock still stacks up against its fundamentals. Ciena has climbed 1.5% over the last week and 12.8% over the past month, while racking up a 159.7% gain year to date and 137.2% over the last year, putting it firmly in the spotlight for momentum focused investors. Much of this strength has been underpinned by growing enthusiasm...

Tyler Technologies recently completed a seven‑month, on‑time and on‑budget rollout of its AWS-powered Enterprise Permitting & Licensing cloud platform for the City of Homestead, Florida, while analysts at TD Cowen began covering the company with a favorable outlook on its public sector software offerings. Together with rising demand for payments and system modernization among state and local governments, these developments underline Tyler’s expanding role in digitizing public services and...